Frontage Holdings (FGHQF) Fair Value & Analysis
Healthcare · US · Market cap $223M
Frontage Holdings
FGHQF · US
Fair value as of: Jul 29, 2026
From 26 valuation models · updated 12 days ago
Share price +11.1% over the past month.
A solid business, but screening 53% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0900). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.1010 – $0.8000 · fair‑value band $0.0500 – $0.0900 · the $0.1500 price screens above the $0.0700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 29, 2026.
Analysis
Frontage Holdings (FGHQF) currently trades at $0.1500, while our model-based Fair Value estimate is $0.0700, implying the stock looks roughly 53.3% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Frontage Holdings generated revenue of $257M at a net margin of 2.7%. Revenue grew 2.9% year over year. It earns a return on equity of 2.0%. Net debt stands at $90.6M. Fundamentals as of Jul 29, 2026
Our scenario range runs from $0.0500 (bear case) to $0.0900 (bull case); at $0.1500, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 1% below its 52-week high and 49% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -53%, FGHQF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models ($0.1700) versus Earnings-Based ($0.0400). Highest evidence: Growth DCF (80).
Notify me when FGHQF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 59
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
Full company description
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing. Further, the company provides laboratory testing services, such as bioanalysis, biomarkers, genomics, chemistry, manufacturing and controls ("CMC") analytical testing, and central laboratory services. It operates in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was founded in 2001 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Consulting Co., ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Frontage Holdings reported revenue of $257M in FY2025 versus $184M in FY2021, a compound +8.7%/yr. Reported net income was $6.8M in FY2025, compounding −22.1%/yr from FY2021.
FGHQF screens 53% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Frontage Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Frontage Holdings (FGHQF) overvalued or undervalued?
What is the fair value of FGHQF?
What is the quality score of FGHQF?
What is the revenue of Frontage Holdings (FGHQF)?
What is the net profit margin of FGHQF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Frontage Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.